$APYX
Apyx Medical Corp Stock $apyx

$apyx Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-Q Financial Statement

#000071913521000072 Filed on November 12, 2021

Income Statement

Concept	2021 Q4	2021 Q3	2020 Q3
Revenue	$16.82M	$11.83M	$6.954M
YoY Change	46.81%	70.13%	-8.2%
Cost Of Revenue	$4.673M	$3.775M	$2.229M
YoY Change	24.28%	69.36%	-2.28%
Gross Profit	$12.15M	$8.056M	$4.725M
YoY Change	57.81%	70.5%	-10.75%
Gross Profit Margin	72.22%	68.09%	67.95%
Selling, General & Admin	$12.90M	$4.611M	$2.706M
YoY Change	45.88%	70.4%	-29.46%
% of Gross Profit	106.13%	57.24%	57.27%
Research & Development	$947.0K	$1.175M	$1.047M
YoY Change	2.93%	12.23%	3.05%
% of Gross Profit	7.79%	14.59%	22.16%
Depreciation & Amortization	$229.0K	$234.0K	$220.0K
YoY Change	-0.43%	6.36%	15.79%
% of Gross Profit	1.88%	2.9%	4.66%
Operating Expenses	$13.84M	$12.02M	$9.096M
YoY Change	41.83%	32.19%	-9.49%
Operating Profit	-$1.692M	-$3.968M	-$4.371M
YoY Change	-17.86%	-9.22%	-8.1%
Interest Expense	$1.000K	$3.000K	$25.00K
YoY Change		-88.0%
% of Operating Profit
Other Income/Expense, Net	-$185.0K	-$193.0K	-$78.00K
YoY Change	-242.31%	147.44%	-114.0%
Pretax Income	-$1.876M	-$4.161M	-$4.449M
YoY Change	-2.29%	-6.47%	5.95%
Income Tax	$134.0K	$73.00K	-$715.0K
% Of Pretax Income
Net Earnings	-$2.003M	-$4.222M	-$3.728M
YoY Change	30.92%	13.25%	-14.69%
Net Earnings / Revenue	-11.91%	-35.69%	-53.61%
Basic Earnings Per Share		-$0.12	-$0.11
Diluted Earnings Per Share	-$58.27K	-$0.12	-$0.11
COMMON SHARES
Basic Shares Outstanding	34.34M shares	34.33M shares	34.22M shares
Diluted Shares Outstanding		34.33M shares	34.22M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$30.87M	$30.90M	$43.50M
YoY Change	-26.32%	-28.97%	-30.18%
Cash & Equivalents	$30.87M	$30.90M	$43.54M
Short-Term Investments
Other Short-Term Assets	$1.926M	$2.967M	$4.200M
YoY Change	-31.21%	-29.36%	147.06%
Inventory	$6.778M	$6.040M	$5.416M
Prepaid Expenses
Receivables	$13.04M	$11.44M	$6.154M
Other Receivables	$483.0K	$873.0K	$1.158M
Total Short-Term Assets	$60.74M	$59.88M	$67.66M
YoY Change	-8.1%	-11.51%	-14.25%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.575M	$6.412M	$6.348M
YoY Change	0.52%	1.01%	-4.47%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.110M	$1.055M	$508.0K
YoY Change	37.55%	107.68%	31.27%
Total Long-Term Assets	$7.984M	$7.893M	$7.751M
YoY Change	-0.47%	1.83%	-3.57%
TOTAL ASSETS
Total Short-Term Assets	$60.74M	$59.88M	$67.66M
Total Long-Term Assets	$7.984M	$7.893M	$7.751M
Total Assets	$68.72M	$67.77M	$75.42M
YoY Change	-7.27%	-10.14%	-13.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.631M	$3.044M	$2.479M
YoY Change	74.12%	22.79%	70.14%
Accrued Expenses	$10.29M	$6.639M	$6.588M
YoY Change	41.34%	0.77%	-9.57%
Deferred Revenue	$533.0K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$165.0K	$218.0K	$400.0K
YoY Change	-17.5%	-45.5%	100.0%
Total Short-Term Liabilities	$13.21M	$11.71M	$9.594M
YoY Change	44.27%	22.07%	6.14%
LONG-TERM LIABILITIES
Long-Term Debt	$18.00K	$22.00K	$300.0K
YoY Change	-91.0%	-92.67%	-50.0%
Other Long-Term Liabilities	$166.0K	$146.0K	$400.0K
YoY Change	0.0%	-63.5%	-33.33%
Total Long-Term Liabilities	$166.0K	$146.0K	$400.0K
YoY Change	0.0%	-63.5%	-66.67%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.21M	$11.71M	$9.594M
Total Long-Term Liabilities	$166.0K	$146.0K	$400.0K
Total Liabilities	$14.71M	$13.11M	$11.08M
YoY Change	43.5%	18.34%	8.49%
SHAREHOLDERS EQUITY
Retained Earnings	-$12.55M	-$10.55M	$4.148M
YoY Change	-578.86%	-354.29%	-79.21%
Common Stock	$34.00K	$34.00K	$34.00K
YoY Change	0.0%	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$53.70M	$54.35M	$64.20M
YoY Change
Total Liabilities & Shareholders Equity	$68.72M	$67.77M	$75.42M
YoY Change	-7.27%	-10.14%	-13.26%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2020 Q3
OPERATING ACTIVITIES
Net Income	-$2.003M	-$4.222M	-$3.728M
YoY Change	30.92%	13.25%	-14.69%
Depreciation, Depletion And Amortization	$229.0K	$234.0K	$220.0K
YoY Change	-0.43%	6.36%	15.79%
Cash From Operating Activities	$214.0K	-$3.605M	-$2.620M
YoY Change	-120.98%	37.6%	-42.29%
INVESTING ACTIVITIES
Capital Expenditures	-$332.0K	-$170.0K	-$10.00K
YoY Change	-14.87%	1600.0%	-98.21%
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change
Cash From Investing Activities	-$332.0K	-$170.0K	-$10.00K
YoY Change	-14.87%	1600.0%	-98.18%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-39.00K	-33.00K	110.0K
YoY Change	-70.0%	-130.0%	266.67%
NET CHANGE
Cash From Operating Activities	214.0K	-3.605M	-2.620M
Cash From Investing Activities	-332.0K	-170.0K	-10.00K
Cash From Financing Activities	-39.00K	-33.00K	110.0K
Net Change In Cash	-157.0K	-3.808M	-2.520M
YoY Change	-89.81%	51.11%	-50.2%
FREE CASH FLOW
Cash From Operating Activities	$214.0K	-$3.605M	-$2.620M
Capital Expenditures	-$332.0K	-$170.0K	-$10.00K
Free Cash Flow	$546.0K	-$3.435M	-$2.610M
YoY Change	-186.67%	31.61%	-34.42%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0000719135
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2021-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	0-12183
	dei	Entity Registrant Name EntityRegistrantName	APYX MEDICAL CORPORATION
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	11-2644611
	dei	Entity Address Address Line1 EntityAddressAddressLine1	5115 Ulmerton Road,
	dei	Entity Address City Or Town EntityAddressCityOrTown	Clearwater
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33760
	dei	City Area Code CityAreaCode	727
	dei	Local Phone Number LocalPhoneNumber	384-2323
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	APYX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	34343750	shares
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30898000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41915000	USD
CY2021Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	360000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	300000	USD
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11444000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8399000	USD
CY2021Q3	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	7654000	USD
CY2020Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	7654000	USD
CY2021Q3	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	873000	USD
CY2020Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1275000	USD
CY2021Q3	apyx	Provision For Obsolescence Inventory ProvisionForObsolescenceInventory	303000	USD
CY2020Q4	apyx	Provision For Obsolescence Inventory ProvisionForObsolescenceInventory	388000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	6040000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	4051000	USD
CY2021Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2967000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2795000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	59876000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	66089000	USD
CY2021Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5145000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4813000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6412000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6541000	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	152000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	237000	USD
CY2021Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	274000	USD
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	437000	USD
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1055000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	807000	USD
CY2021Q3	us-gaap	Assets Assets	67769000	USD
CY2020Q4	us-gaap	Assets Assets	74111000	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	3044000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1511000	USD
CY2021Q3	apyx	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	8324000	USD
CY2020Q4	apyx	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	7278000	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	125000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	126000	USD
CY2021Q3	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	218000	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	238000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	11711000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9153000	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	30000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	129000	USD
CY2021Q3	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	22000	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	183000	USD
CY2021Q3	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1200000	USD
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	64862000	USD
CY2021Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	146000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	621000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	166000	USD
CY2021Q3	us-gaap	Liabilities Liabilities	13109000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	10252000	USD
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2021Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34339533	shares
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34339533	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34289222	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34289222	shares
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	34000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	34000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	10243000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	6444000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	61066000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-10548000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	2621000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	54348000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	63721000	USD
CY2021Q3	us-gaap	Minority Interest MinorityInterest	312000	USD
CY2020Q4	us-gaap	Minority Interest MinorityInterest	138000	USD
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	54660000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	63859000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	67769000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	74111000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11831000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6954000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	31693000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16247000	USD
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3775000	USD
CY2020Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2229000	USD
CY2021Q3	us-gaap	Gross Profit GrossProfit	8056000	USD
CY2020Q3	us-gaap	Gross Profit GrossProfit	4725000	USD
	us-gaap	Gross Profit GrossProfit	21450000	USD
	us-gaap	Gross Profit GrossProfit	9803000	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1175000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1047000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3374000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3002000	USD
CY2021Q3	us-gaap	Professional Fees ProfessionalFees	2032000	USD
CY2020Q3	us-gaap	Professional Fees ProfessionalFees	1835000	USD
	us-gaap	Professional Fees ProfessionalFees	5442000	USD
	us-gaap	Professional Fees ProfessionalFees	5882000	USD
CY2021Q3	us-gaap	Salaries And Wages SalariesAndWages	4206000	USD
CY2020Q3	us-gaap	Salaries And Wages SalariesAndWages	3508000	USD
	us-gaap	Salaries And Wages SalariesAndWages	12794000	USD
	us-gaap	Salaries And Wages SalariesAndWages	10258000	USD
CY2021Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	4611000	USD
CY2020Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2706000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12596000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8691000	USD
CY2021Q3	us-gaap	Operating Expenses OperatingExpenses	12024000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	9096000	USD
	us-gaap	Operating Expenses OperatingExpenses	34206000	USD
	us-gaap	Operating Expenses OperatingExpenses	27833000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3968000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4371000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12756000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18030000	USD
CY2021Q3	us-gaap	Interest Income Operating InterestIncomeOperating	2000	USD
CY2020Q3	us-gaap	Interest Income Operating InterestIncomeOperating	10000	USD
	us-gaap	Interest Income Operating InterestIncomeOperating	9000	USD
	us-gaap	Interest Income Operating InterestIncomeOperating	233000	USD
CY2021Q3	us-gaap	Interest Expense InterestExpense	3000	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	25000	USD
	us-gaap	Interest Expense InterestExpense	9000	USD
	us-gaap	Interest Expense InterestExpense	39000	USD
CY2021Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-192000	USD
CY2020Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-63000	USD
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-188000	USD
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	349000	USD
CY2021Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-193000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-78000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-188000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	543000	USD
CY2021Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4161000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4449000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12944000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17487000	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	73000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-715000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	246000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7112000	USD
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-4234000	USD
CY2020Q3	us-gaap	Profit Loss ProfitLoss	-3734000	USD
	us-gaap	Profit Loss ProfitLoss	-13190000	USD
	us-gaap	Profit Loss ProfitLoss	-10375000	USD
CY2021Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-12000	USD
CY2020Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-6000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-21000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-6000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-4222000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-3728000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-13169000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-10369000	USD
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.38
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.38
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.30
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.30
CY2020Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	66836000	USD
CY2020Q3	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	148000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	25000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1063000	USD
CY2020Q3	us-gaap	Profit Loss ProfitLoss	-3734000	USD
CY2020Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	64338000	USD
CY2021Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	57682000	USD
CY2021Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	28000	USD
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1184000	USD
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-4234000	USD
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	54660000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	71259000	USD
	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	148000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	97000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3209000	USD
	us-gaap	Profit Loss ProfitLoss	-10375000	USD
CY2020Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	64338000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	63859000	USD
	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	195000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	49000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3747000	USD
	us-gaap	Profit Loss ProfitLoss	-13190000	USD
CY2021Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	54660000	USD
	us-gaap	Profit Loss ProfitLoss	-13190000	USD
	us-gaap	Profit Loss ProfitLoss	-10375000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	674000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	662000	USD
	apyx	Provision For Inventory Obsolescence ProvisionForInventoryObsolescence	15000	USD
	apyx	Provision For Inventory Obsolescence ProvisionForInventoryObsolescence	427000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-47000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3747000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3209000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	57000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	486000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3168000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1389000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	23000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	981000	USD
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	0	USD
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	6812000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1982000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	717000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1555000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	15000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	1605000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2352000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10663000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15049000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	391000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	193000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-391000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-193000	USD
	apyx	Proceeds From Stock Options Exercised And Warrants Exercised ProceedsFromStockOptionsExercisedAndWarrantsExercised	49000	USD
	apyx	Proceeds From Stock Options Exercised And Warrants Exercised ProceedsFromStockOptionsExercisedAndWarrantsExercised	97000	USD
	apyx	Repaymentof Finance Lease Liabilities RepaymentofFinanceLeaseLiabilities	181000	USD
	apyx	Repaymentof Finance Lease Liabilities RepaymentofFinanceLeaseLiabilities	184000	USD
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	195000	USD
	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	148000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	63000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	61000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-26000	USD
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-92000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-11017000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-15273000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	41915000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	58812000	USD
CY2021Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	30898000	USD
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	43539000	USD
	us-gaap	Interest Paid Net InterestPaidNet	8000	USD
	us-gaap	Interest Paid Net InterestPaidNet	39000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	13000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	54000	USD
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reclassified certain amounts presented in the prior period to conform to the current period presentation. These reclassifications had no impact on previously reported net loss, retained earnings or net cash used in operating activities for the periods presented.</span></div>
CY2018Q3	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	97000000	USD
CY2021Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	3505000	USD
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2243000	USD
CY2021Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	1284000	USD
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1109000	USD
CY2021Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1554000	USD
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1087000	USD
CY2021Q3	us-gaap	Inventory Gross InventoryGross	6343000	USD
CY2020Q4	us-gaap	Inventory Gross InventoryGross	4439000	USD
CY2021Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	303000	USD
CY2020Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	388000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	6040000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	4051000	USD
CY2021Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	894000	USD
CY2020Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	808000	USD
CY2021Q3	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	1559000	USD
CY2020Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	811000	USD
CY2021Q3	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	897000	USD
CY2020Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	1001000	USD
CY2021Q3	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	547000	USD
CY2020Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	498000	USD
CY2021Q3	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	440000	USD
CY2020Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	435000	USD
CY2021Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	252000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	222000	USD
CY2021Q3	apyx	Joint And Several Payroll Liability JointAndSeveralPayrollLiability	1027000	USD
CY2020Q4	apyx	Joint And Several Payroll Liability JointAndSeveralPayrollLiability	1027000	USD
CY2021Q3	apyx	Uncertain Tax Positions Liability UncertainTaxPositionsLiability	1810000	USD
CY2020Q4	apyx	Uncertain Tax Positions Liability UncertainTaxPositionsLiability	1658000	USD
CY2021Q3	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	243000	USD
CY2020Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	591000	USD
CY2021Q3	apyx	Other Accrued Expenses And Liabilities Current OtherAccruedExpensesAndLiabilitiesCurrent	655000	USD
CY2020Q4	apyx	Other Accrued Expenses And Liabilities Current OtherAccruedExpensesAndLiabilitiesCurrent	227000	USD
CY2021Q3	apyx	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	8324000	USD
CY2020Q4	apyx	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	7278000	USD
CY2019Q4	apyx	Noncontrolling Interest Required Capital Contribution NoncontrollingInterestRequiredCapitalContribution	357000	USD
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4222000	USD
CY2021Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4222000	USD
CY2020Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3728000	USD
CY2020Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-3728000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13169000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-13169000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-10369000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10369000	USD
CY2021Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34330000	shares
CY2021Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34330000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34216000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34216000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34318000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34318000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	34193000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	34193000	shares
CY2021Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2021Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.38
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.38
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.30
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.30
CY2021Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1184000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3747000	USD
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1063000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3209000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4938943	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.46
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	894980	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	9.37
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	109415	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.26
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	190793	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	8.22
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5533715	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.98
CY2021Q3	apyx	Stock Issued During Period Shares Stock Swaps Equity Instruments Received StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived	37049	shares
CY2020Q3	apyx	Stock Issued During Period Shares Stock Swaps Equity Instruments Received StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived	16140	shares
CY2021Q3	apyx	Stock Issued During Period Shares Stock Swaps StockIssuedDuringPeriodSharesStockSwaps	13285	shares
CY2020Q3	apyx	Stock Issued During Period Shares Stock Swaps StockIssuedDuringPeriodSharesStockSwaps	10610	shares
	apyx	Stock Issued During Period Shares Stock Swaps Equity Instruments Received StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived	59104	shares
	apyx	Stock Issued During Period Shares Stock Swaps Equity Instruments Received StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived	29149	shares
	apyx	Stock Issued During Period Shares Stock Swaps StockIssuedDuringPeriodSharesStockSwaps	39312	shares
	apyx	Stock Issued During Period Shares Stock Swaps StockIssuedDuringPeriodSharesStockSwaps	32637	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	apyx	Cares Act Income Tax Expense Benefit Release Of Valuation Allowance Federal Net Operating Loss Carryforwards CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards	-3700000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-700000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7100000	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	73000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-715000	USD
CY2021Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.018
CY2020Q3	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.161
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	246000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7112000	USD
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.019
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.407
CY2021Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1313000	USD
CY2021Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	497000	USD
CY2021Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	52000	USD
CY2020Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	43000	USD
	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	152000	USD
	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	125000	USD
CY2021Q3	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	1810000	USD
CY2021Q3	us-gaap	Purchase Obligation PurchaseObligation	5200000	USD
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11831000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3968000	USD
CY2021Q3	us-gaap	Interest Income Operating InterestIncomeOperating	2000	USD
CY2021Q3	us-gaap	Interest Expense InterestExpense	3000	USD
CY2021Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-192000	USD
CY2021Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	73000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6954000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4371000	USD
CY2020Q3	us-gaap	Interest Income Operating InterestIncomeOperating	10000	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	25000	USD
CY2020Q3	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-63000	USD
CY2020Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-715000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	31693000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12756000	USD
	us-gaap	Interest Income Operating InterestIncomeOperating	9000	USD
	us-gaap	Interest Expense InterestExpense	9000	USD
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-188000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	246000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16247000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18030000	USD
	us-gaap	Interest Income Operating InterestIncomeOperating	233000	USD
	us-gaap	Interest Expense InterestExpense	39000	USD
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	349000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7112000	USD
CY2021Q3	apyx	Total Revenue Percent TotalRevenuePercent	0.331
	apyx	Total Revenue Percent TotalRevenuePercent	0.342
CY2020Q3	apyx	Total Revenue Percent TotalRevenuePercent	0.250
	apyx	Total Revenue Percent TotalRevenuePercent	0.248
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	11831000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6954000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	31693000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16247000	USD

Files In Submission

Name	View Source	Status
0000719135-21-000072-index-headers.html	Edgar Link	pending
0000719135-21-000072-index.html	Edgar Link	pending
0000719135-21-000072.txt	Edgar Link	pending
0000719135-21-000072-xbrl.zip	Edgar Link	pending
a2021q310-qexhibit311.htm	Edgar Link	pending
a2021q310-qexhibit312.htm	Edgar Link	pending
a2021q310-qexhibit321.htm	Edgar Link	pending
a2021q310-qexhibit322.htm	Edgar Link	pending
apyx-20210930.htm	Edgar Link	pending
apyx-20210930.xsd	Edgar Link	pending
apyx-20210930_cal.xml	Edgar Link	unprocessable
apyx-20210930_def.xml	Edgar Link	unprocessable
apyx-20210930_g1.jpg	Edgar Link	pending
apyx-20210930_htm.xml	Edgar Link	completed
apyx-20210930_lab.xml	Edgar Link	unprocessable
apyx-20210930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$APYX
Apyx Medical Corp Stock $apyx

2021 Q4 Form 10-Q Financial Statement

#000071913521000072 Filed on November 12, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APYX Apyx Medical Corp Stock $apyx

2021 Q4 Form 10-Q Financial Statement

#000071913521000072 Filed on November 12, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APYX
Apyx Medical Corp Stock $apyx